Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

To evaluate if rovalpituzumab tesirine improves progression-free and overall survival.

This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study. ED SCLC patients who demonstrate ongoing clinical benefit at the completion of 4 cycles of first-line platinum-based chemotherapy will be randomly assigned in a 1:1 ratio to receive rovalpituzumab tesirine or placebo.

Patient Profile

Patients with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing clinical benefit following completion of 4 cycles of first-line platinum-based chemotherapy.

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, and University Hospital Waterford

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: AbbVie MERU
Number: 16-80
Full Title:

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU).

Principal Investigator: Dr Linda Coate (University Hospital Limerick)
Type: Industry Sponsored
Recruitment Started: Global: April 2017
Ireland: September 2017
Global Recruitment Target: 711
Ireland Recruitment Target: 12